地西他滨联合半量预激方案治疗骨髓增生异常综合征的效果  

Effect of Decitabine combined with half-dose priming regimen in the treatment of myelodysplastic syndrome

作　　者：荆雷[1] JING Lei(Department of Hematology,Dandong Central Hospital,Liaoning Province,Dandong 118000,China)

机构地区：[1]辽宁省丹东市中心医院血液病,辽宁丹东118000

出　　处：《中国当代医药》2023年第1期79-82,共4页China Modern Medicine

摘　　要：目的探讨地西他滨(DAC)联合半量预激方案治疗骨髓增生异常综合征(MDS)的效果。方法选取2017年4月至2020年4月丹东市中心医院收治的62例MDS患者作为研究对象进行回顾性分析,根据治疗方式的不同将其分为对照组(30例)和观察组(32例)。对照组患者使用标准化疗方案进行治疗,观察组患者使用DAC联合半量预激方案进行治疗。比较两组患者治疗1个疗程后的治疗效果;比较两组患者治疗前、治疗1个疗程后的血细胞计数[白细胞(WBC)、血小板(PLT)];统计治疗期间两组患者的毒副反应发生情况。结果治疗1个疗程后,观察组患者的治疗效果优于对照组,治疗总有效率(84.37%)高于对照组(60.00%),差异有统计学意义(χ^(2)=4.622,P=0.031);两组患者治疗后的WBC、PLT均高于治疗前,且观察组患者治疗后的WBC、PLT高于对照组,差异有统计学意义(P<0.05)。治疗期间观察组患者的毒副反应总发生率(6.24%)低于对照组(30.00%),差异有统计学意义(χ^(2)=4.467,P=0.034)。结论DAC联合半量预激方案治疗MDS具有较好的效果,能改善患者的血细胞情况,且毒副反应较小,值得临床应用推广。Objective To explore the effect of Decitabine(DAC)combined with half-dose priming regimen in the treatment of myelodysplastic syndrome(MDS).Methods A total of 62 patients with MDS admitted to Dandong Central Hospital between April 2017 and April 2020 were selected as the study subjects for retrospective analysis.According to the different treatment methods,the patients were divided into control group(n=30)and observation group(n=32).The patients in the control group were treated with standard chemotherapy regimen,while the patients in observation group were given DAC combined with half-dose priming regimen.The therapeutic effect was compared between the two groups after 1 course of treatment.Blood cell counts(white blood cells[WBC],platelet count[PLT])were compared between the two groups before treatment and after 1 course of treatment.The occurrence of toxic and side effects in the two groups during the treatment were analyzed.Results After one course of treatment,the treatment effect of observation group was better than that of control group,the total effective rate of observation group(84.37%)was higher than that of control group(60.00%),the differences were statistically significant(χ2=4.622,P=0.031).The WBC and PLT of the two groups after treatment were higher than those before treatment,and the WBC and PLT of observation group after treatment were higher than those in the control group,the differences were statistically significant(P<0.05).The total incidence of toxic and side effects in observation group(6.24%)was lower than that in control group(30.00%),the difference was statistically significant(χ2=4.467,P=0.034).Conclusion DAC combined with half-dose priming regimen has high efficacy in the treatment of MDS,and can improve the blood cells of patients and it has small toxic and side effects,therefore it is worthy of clinical application and promotion.

关 键 词：地西他滨 半量预激方案 骨髓增生异常综合征 毒副反应 

分 类 号：R733[医药卫生—肿瘤]